Skip Navigation


NDT Advance Access originally published online on November 7, 2008
Nephrology Dialysis Transplantation 2009 24(2):341-344; doi:10.1093/ndt/gfn624
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/2/341    most recent
gfn624v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Negri, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Negri, A. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD

Armando L. Negri

Instituto de Investigaciones Metabólicas, Universidad del Salvador School of Medicine, Buenos Aires, Argentina

Correspondence and offprint requests to: Armando Luis Negri, Instituto de Investigaciones Metabólicas, Libertad 836 1 piso, Buenos Aires 1012, Argentina. Tel: +54-1-50319700; Fax: +5411-4633-3838, Ext. 220; E-mail: negri@casasco.com.ar

Keywords: haemodialysis; oral calcitriol; predialysis; survival

The first 150 words of the full text of this article appear below.



   Introduction
 
A large body of evidence suggests that vitamin D has health benefits beyond its central role in calcium-phosphorus homeostasis, regulation of PTH and formation and maintenance of bone [1]. Activated vitamin D binds to the vitamin D receptor (VDR) and influences diverse genetic responses in many tissues. This is because VDR is expressed not only in the classical target organs (bone, parathyroid glands, kidneys and intestine) but also in other non-classical targets including arteries, heart, immune system, endocrine organs and even the nervous system [1].

Vitamin D can inhibit various aspects of inflammation, which have been established as a key pathogenic mechanism in atherosclerosis: Vitamin D through VDR activation increases the Th2 cell population of lymphocytes [2]. Th2 lymphocytes are antiatherogenic through their production of IL-10 [3] that is upregulated by calcitriol [4], inhibiting macrophage activation. Calcitriol also inhibits interferon . . . [Full Text of this Article]



   Parenteral administration of VDRAs and survival
 


   Oral administration of calcitriol and improved survival
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?